Outre-Atlantique, les outils en ligne se diffusent rapidement dans le domaine de la santé. Une tendance croissante qui, en donnant plus d'autonomie et d'information au patient, modifie complètement la relation patient-médecin.
Chargée du débat sur l’ouverture des données publiques de santé, la Commission Open-Data, constituée en novembre 2013, a achevé ses travaux. Elle remet aujourd’hui son rapport à Marisol Touraine, ministre des Affaires sociales et de la Santé. Certaines de ses propositions seront mises en œuvre dès cette année.
Many in the health care industry are wary of jumping on the social media bandwagon due to legal limitations, fear of exposing privileged information, and damaging relationships with patients and partners. Be that as it may, social networking is just too big for many people to ignore.
Stats from Nielsen report that sites like Facebook and Twitter now account for 22.7% of the time spent on the Internet. In comparison, E-mail as a percentage of online time use has plunged from 11.5% to 8.3% from June 2009 to June 2010.
Social media marketing in health care can be an easy way to stay connected with customers and prospects. The good news is that utilizing social networking sites, such as Google+, Facebook, Twitter, YouTube, and LinkedIn, doesn’t have to be scary. Social media disaster can easily be avoided by following simple guidelines and methods.
The American Medical Association suggests the following as basics for all clinicians using social media. These basics can easily be applied to product manufacturers, as well:
Remain business focused and define a clear intent for your social media accounts.Maintain a positive and professional presence.Make use of privacy settings and monitor your Internet presence.Maintain appropriate relationships with “friends” and “followers” and set boundaries.Monitor posts, respond to comments, and filter out the bad.Report misuse of social media by colleagues.Don’t post any identifiable patient information. The doctor/ patient confidentiality relationship also applies to online interactions.
Mayo Clinic suggests speaking in the first person and distinguishing personal thoughts and beliefs from those of your organization. The Mayo Clinic also stresses the importance of disclosing a connection to the company you are associated with when communicating public interest about the organization.
So what is there to talk about? Here are a few ideas to get you started:
Share news related to your industry.Share good news about what is happening at your company.Interact with other businesses and professionals related to your company or industry.Interact with customers by asking general questions related to your industry.
Kestrel Health Information maintains a presence on LinkedIn, Twitter, Google+ and Facebook, connecting with both clinicians and product manufacturers alike. Through a combination of product-related information and niche specific news media, these social media sites provide valuable points of contact, as well as a platform for industry-related discussions.
The purpose of social media is to interact, and build relationships. It allows customers to forge personal connections with professionals and businesses that were not previously possible.
For a business this can mean building a loyal customer base, or utilizing customer feedback in order to improve service. It can also help your company generate new leads to convert into new customers.
Follow these suggestions and begin using social media to increase your visibility right away.
Two NEW FDA DRAFT Guidances On the Use of Social Media and Online Promotions of Devices and Drugs
After five years in the making, the FDA is on a roll. Following the publication of the previous draft guidance on the use of social media for “post-marketing submissions for post marketing submissions of interactive promotional media“, the agency has published two new guidances of conduct of medical device and pharma companies in social media.
The first seems easier to understand and implement than the second.
Draft Guidance I: Correcting independent third-party misinformation about prescription drugs and medical devices
Imagine the following: You work as a sales representative in a medical device company. It has come to your attention that a blogger wrote a post that contains inaccurate information about your medical device. On the same day, you learn of a patient that has shared personal experiences with your device on a forum and misinformed other patients about the device’s use. You believe that the way that both these stories are represented may be harmful to the public health. You start typing away at your answer, informing the blogger and forum members of their mistakes. FDA guidance suggests that you should stop first and ask yourself: is it worth your while?
The FDA maintains that you have no obligation to correct any information published by a third party who is not under the firm’s control or influence. This is regardless of whether the firm owns or operates the platform on which the communication appears.
The FDA leaves this to the discretion of the pharma company or medical devices company. If the company chooses to engage in the correction of misinformation, it needs to adhere to certain approaches outlined in the guidance – for instance it cannot only correct negative misinformation written about the medical device while ignoring an overstatement of the benefits of the product.
Download complete draft FDA social media guidance on Correcting Independent Third-Party Misinformation about Prescription Drugs and Medical Devices.
Draft Guidance II: Internet/social media platforms with character space limitations
This FDA draft guidance is more comprehensive than the first and seems more complicated to execute. The guidance describes the FDA’s current thinking about how medical devices and drug manufacturers and marketers should present benefit and risk information of promotional materials in channels that have “character space limitations” (mainly Twitter, and “sponsored links” on search engines such as Google). The guidance does not include platforms such as Facebook and YouTube where there are no space limitations.
The main takeaway: Risk information must appear alongside risk information. Both must be presented in the same message. The FDA clearly states that having risk information on only a Twitter cover photo is insufficient and that main risk information should be included in the short message as well. If a medical company concludes that adequate benefit and risk information, as well as other required information, cannot all be communicated within the same character-space-limited communication, then the firm should reconsider using that platform for the intended promotional message. To many companies, this will be the case. To make matters more complicated, a link should be should be supplied that brings visitors to a page that is solely dedicated to risk information.
The guidance on how promotional materials should be prepared and presented goes on at length in its recommendation – using the example of a fictional drug they call NoFocus (And some people say that the FDA has no humor….).
The use of so many examples shows how complex this field is and the extent to which the FDA does not have a clear grasp of the way it should be managed.
Download complete draft FDA social media guidance on Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices
La Haute Autorité de Santé a publié jeudi 3 séries de données en open data. Disponibles sur le site de la HAS et à partir du site data.gouv.fr, la HAS met à disposition les données d’évaluation des médicaments, les indicateurs de qualité et de sécurité des soins et les données de la certification des établissements de santé français.
Big data analytics technology has been able to find patterns and pinpoint disease states more accurately than even the most highly-trained physicians.
The human brain may be nature’s finest computer, but artificial intelligences fed on big data are making a convincing challenge for the crown. In the realm of healthcare, natural language processing, associative intelligence, and machine learning are revolutionizing the way physicians make decisions and diagnose complex patients, significantly improving accuracy and catching deadly issues before symptoms even present themselves.
In this case study examining the impact of big data analytics on clinical decision making, Dr. Partho Sengupta, Director of Cardiac Ultrasound Research and Associate Professor of Medicine in Cardiology at the Mount Sinai Hospital, has used an associative memory engine from Saffron Technology to crunch enormous datasets for more accurate diagnoses.
Using 10,000 attributes collected from 90 metrics in six different locations of the heart, all produced by a single, one-second heartbeat, the analytics technology has been able to find patterns and pinpoint disease states more quickly and accurately than even the most highly-trained physicians.
Science-fiction bonjour ! Certains hôpitaux sont capables d'identifier les patients à haut risque grâce à leurs données de consommation. Ils utilisent les informations issues des cartes de crédit et de fidélité pour générer des algorithmes et ainsi intervenir avant que le sujet ne tombe malade.
Le HealthCare System est actuellement en train d’être testé sur deux millions de personnes… Comment ça marche? Prenez, par exemple, un patient asthmatique. Il suffit d’anticiper avant le drame, et pour se faire l’hôpital peut brasser pléthore de données, comme les médicaments achetés, les cigarettes, ou encore s’il vit dans une zone emplie de pollen.
Les bracelets connectés et autres trackers ainsi que les données recueillies sont le plus souvent utilisés dans les secteurs de la santé ou du fitness.La start-up Lightwave s'intéresse, de son côté, aux activités liées à la fête et à la nuit. Sa plateforme est capable d'analyser les données biométriques issues des dispositifs portables connectés, comme la consommation d'alcool, la température et les mouvements du corps ou le rythme cardiaque.Lightwave peut ainsi offrir une vision d'ensemble et en temps réel de l'état d'un public à un concert ou dans une boîte de nuit. De quoi permettre aux artistes et aux organisateurs d'agir en conséquence ou d'analyser, par la suite, les musiques ou animations qui ont eu le plus d'impact.En plus de fournir des données objectives sur la qualité d'une soirée, le dispositif pourrait également être utilisé pour déclencher des animations automatiques (jets de fumée, jeux de lumière etc.) en fonction de l'ambiance de la salle.Crédit Photo : Creative Commons / Flickr / messycupcakes